Free Trial

ZyVersa Therapeutics (ZVSA) Competitors

ZyVersa Therapeutics logo
$0.27 +0.03 (+12.50%)
As of 07/25/2025 03:58 PM Eastern

ZVSA vs. ALZN, ADTX, PTN, JAGX, ENTO, APVO, SCNI, GRTX, SXTP, and ONCO

Should you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Alzamend Neuro (ALZN), Aditxt (ADTX), Palatin Technologies (PTN), Jaguar Animal Health (JAGX), Entero Therapeutics (ENTO), Aptevo Therapeutics (APVO), Scinai Immunotherapeutics (SCNI), Galera Therapeutics (GRTX), 60 Degrees Pharmaceuticals (SXTP), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry.

ZyVersa Therapeutics vs. Its Competitors

ZyVersa Therapeutics (NASDAQ:ZVSA) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Alzamend Neuro has a consensus price target of $180.00, indicating a potential upside of 5,981.08%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than ZyVersa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ZyVersa Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Alzamend Neuro
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

ZyVersa Therapeutics' return on equity of -109.54% beat Alzamend Neuro's return on equity.

Company Net Margins Return on Equity Return on Assets
ZyVersa TherapeuticsN/A -109.54% -43.95%
Alzamend Neuro N/A -181.34%-116.84%

ZyVersa Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.31, suggesting that its stock price is 131% less volatile than the S&P 500.

In the previous week, Alzamend Neuro had 3 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 5 mentions for Alzamend Neuro and 2 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.93 beat Alzamend Neuro's score of -0.28 indicating that ZyVersa Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ZyVersa Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alzamend Neuro
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by company insiders. Comparatively, 30.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ZyVersa TherapeuticsN/AN/A-$9.41MN/AN/A
Alzamend NeuroN/AN/A-$9.95MN/AN/A

Summary

Alzamend Neuro beats ZyVersa Therapeutics on 6 of the 11 factors compared between the two stocks.

Get ZyVersa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZVSA vs. The Competition

MetricZyVersa TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.32M$3.06B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E RatioN/A21.1828.1020.05
Price / SalesN/A288.50432.4490.07
Price / CashN/A42.7636.2258.56
Price / Book0.088.378.665.87
Net Income-$9.41M-$55.19M$3.25B$258.55M
7 Day Performance88.81%5.88%4.23%3.74%
1 Month Performance-60.26%17.33%10.52%11.75%
1 Year Performance-92.99%4.42%34.41%18.03%

ZyVersa Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZVSA
ZyVersa Therapeutics
0.1938 of 5 stars
$0.27
+12.5%
N/A-93.0%$1.32MN/A0.002Gap Up
ALZN
Alzamend Neuro
2.6808 of 5 stars
$3.19
-2.1%
$180.00
+5,537.3%
-91.5%$2.60MN/A0.004News Coverage
Upcoming Earnings
Insider Trade
ADTX
Aditxt
N/A$1.20
+1.3%
N/A-100.0%$2.52M$55.32K0.0060
PTN
Palatin Technologies
N/A$0.09
-44.6%
N/AN/A$2.45M$350K-0.0630Gap Down
High Trading Volume
JAGX
Jaguar Animal Health
2.8716 of 5 stars
$2.37
-1.7%
$60.00
+2,431.6%
-93.4%$2.41M$11.55M0.0050
ENTO
Entero Therapeutics
N/A$0.49
-1.0%
N/A-51.0%$2.34MN/A0.009
APVO
Aptevo Therapeutics
2.4985 of 5 stars
$3.02
-1.0%
$219,040.00
+7,252,880.1%
-100.0%$2.31M$3.11M0.0050Positive News
Gap Up
SCNI
Scinai Immunotherapeutics
1.7577 of 5 stars
$2.20
+2.3%
N/A-45.4%$2.20M$658K-0.2320
GRTX
Galera Therapeutics
N/A$0.03
+5.9%
N/A-80.0%$2.04MN/A-0.0830
SXTP
60 Degrees Pharmaceuticals
2.8103 of 5 stars
$1.35
-2.6%
$7.00
+417.0%
+39.4%$2.01M$300K-0.033
ONCO
Onconetix
0.3253 of 5 stars
$3.72
-2.1%
N/A-99.2%$2.00M$1.93M0.0012

Related Companies and Tools


This page (NASDAQ:ZVSA) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners